| scholarly article | Q13442814 |
| P50 | author | Hasan Korkaya | Q62592865 |
| P2093 | author name string | Lu Xue | |
| Xiaolin Yu | |||
| Haitao Liu | |||
| Lijing Zhao | |||
| Daqing Wu | |||
| Shou-Ching Tang | |||
| Nita J Maihle | |||
| Sharad Ghamande | |||
| Shuhua Zhao | |||
| Hong Yan Liu | |||
| Wenxi Tan | |||
| P2860 | cites work | Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity | Q38882857 |
| Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. | Q38942597 | ||
| PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells | Q39494655 | ||
| EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance | Q39783093 | ||
| Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells | Q39874639 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Q40009294 | ||
| Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network | Q40093663 | ||
| Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase | Q40584437 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast | Q46402523 | ||
| Aptamers as therapeutics. | Q51813594 | ||
| PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice | Q84398421 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling | Q24794988 | ||
| Bispecific antibodies | Q27027186 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| In vitro selection of RNA molecules that bind specific ligands | Q27861109 | ||
| Progress toward in vivo use of siRNAs-II | Q28255877 | ||
| Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain | Q28262499 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth | Q33588273 | ||
| ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics | Q33601653 | ||
| Aptamer-targeted antigen delivery | Q33870736 | ||
| In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells | Q33958666 | ||
| Complement-targeted therapeutics | Q34255011 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. | Q34492647 | ||
| Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras | Q35015737 | ||
| An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice | Q35111705 | ||
| Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. | Q35234347 | ||
| High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. | Q36139325 | ||
| Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. | Q36603032 | ||
| c-erbB-4 protein expression in human breast cancer | Q36621288 | ||
| Trastuzumab: triumphs and tribulations | Q36832109 | ||
| Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer | Q37125328 | ||
| Chemical modification of siRNAs for in vivo use. | Q37331765 | ||
| Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. | Q37469987 | ||
| Therapeutic RNA aptamers in clinical trials | Q38059064 | ||
| Aptamers as targeted therapeutics: current potential and challenges | Q38290290 | ||
| Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab | Q38757863 | ||
| HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models | Q38760738 | ||
| A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response | Q38793980 | ||
| Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers | Q38856785 | ||
| P304 | page(s) | 317-330 | |
| P577 | publication date | 2017-12-30 | |
| P1433 | published in | Molecular Therapy. Nucleic acids | Q27724110 |
| P1476 | title | Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer | |
| P478 | volume | 10 |
| Q89791186 | A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo |
| Q58584175 | Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives |
| Q57812842 | Aptamer-iRNAs as Therapeutics for Cancer Treatment |
| Q92327243 | Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer |
| Q97568985 | Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment |
| Q90291164 | Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras |
| Q92406179 | Lipid Profile and Aquaporin Expression under Oxidative Stress in Breast Cancer Cells of Different Malignancies |
| Q90316294 | MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer |
| Q58728275 | Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth |
Search more.